Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 243 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Clostridium Infections Clear all
Not listed Not applicable Interventional

Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.

NCT00377078
View directory record Official record
Conditions
Clostridium Difficile
Interventions
recombinant human lactoferrin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2006 · Synced Sep 9, 2026, 11:06 PM EDT
Terminated Phase 4 Interventional

Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury

NCT02355938
View directory record Official record
Conditions
Clostridium Difficile, Spinal Cord Injury
Interventions
Fidaxomicin 200 mg, Placebo, Vancomycin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Phase 3 Interventional Results available

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

NCT03182907
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 9, 2026, 11:06 PM EDT
Not yet recruiting Phase 4 Interventional

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

NCT06794944
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions
Vancomycin (POC), Fidaxomicin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 9, 2026, 11:06 PM EDT
Withdrawn Not applicable Interventional

EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota Transplant

NCT02968511
View directory record Official record
Conditions
C.Difficile Colitis
Interventions
fecal microbiota transplant
Biological
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2017 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clostridium Difficile Vaccine Efficacy Trial

NCT03090191
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Clostridium difficile vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
17,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
220
States / cities
Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PFAS Exposure and Immune Response to Vaccination in Adults

NCT06588530
View directory record Official record
Conditions
Innate Inflammatory Response, Vaccination, Diphtheria, Tetanus, Environmental Exposure, Vaccine, Antibodies, Adult, Immunity, Pollution; Exposure
Interventions
TENIVAC
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Paulsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

NCT00282295
View directory record Official record
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Boostrix®, Menactra™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years
Enrollment
1,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
24
States / cities
Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 9, 2026, 11:06 PM EDT
Not yet recruiting Early Phase 1 Interventional

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

NCT06884748
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ursodiol 500 MG
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 9, 2026, 11:06 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

NCT00466635
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous, Diarrhea, Clostridium Difficile
Interventions
GT267-004 (tolevamer potassium sodium)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Modesto, California • Honolulu, Hawaii • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

NCT00777257
View directory record Official record
Conditions
Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions
T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 17 Years
Enrollment
1,345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
20
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 9, 2026, 11:06 PM EDT
Recruiting Not applicable Interventional

Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)

NCT07613645
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Health counseling sessions, Diet (control diet), Diet (experimental diet)
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Early Phase 1 Interventional

Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis

NCT03268213
View directory record Official record
Conditions
Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis
Interventions
Fecal Microbial Transplantation
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
7 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 9, 2026, 11:06 PM EDT
Terminated Phase 2 Interventional Results available

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection

NCT02053350
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Alanyl-glutamine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 9, 2026, 11:06 PM EDT
Terminated Phase 2 Interventional Results available

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

NCT03973697
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection
Interventions
Penn Microbiome Therapy - 001, Penn Microbiome Therapy - 002, Penn Microbiome Therapy - 003
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 11:06 PM EDT
Terminated Phase 2 Interventional Results available

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

NCT03617445
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 9, 2026, 11:06 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

NCT01439165
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine, Tetanus and Diphtheria Toxoids Adsorbed For Adult Use
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
31
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 9, 2026, 11:06 PM EDT
Recruiting Phase 1 Interventional

Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection

NCT06370884
View directory record Official record
Conditions
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Interventions
IMT
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

NCT00350298
View directory record Official record
Conditions
Clostridium Infections
Interventions
GS-CDA1/MDX-1388, normal saline
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

NCT00269399
View directory record Official record
Conditions
Clostridium Infections, Diarrhea
Interventions
Rifaximin (Xifaxan), Vancomycin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
63
States / cities
Scottsdale, Arizona • Redlands, California • Longmont, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Not applicable Interventional

High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology

NCT04940468
View directory record Official record
Conditions
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
Interventions
Diet Intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 9, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

Study of CB-183,315 in Participants With Clostridium Difficile Infection

NCT01085591
View directory record Official record
Conditions
Clostridium Difficile Infection, Diarrhea
Interventions
CB-183,315, Placebo, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Saint Cloud, Florida • Decatur, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 9, 2026, 11:06 PM EDT